Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
PURPOSE: This study explored the barriers that adult Americans experience when taking injectable medications for type 2 diabetes, from the time of filling the initial prescription through the decision to discontinue the medication. METHODS: An Internet-based survey was conducted in 2 waves among adult patients (N = 2000) who had received a physician prescription for insulin, liraglutide, or exenatide once weekly (QW), regardless of whether the prescription was filled by a pharmacy. In wave 1, patients were surveyed on their medication history and experience and, if relevant, the medication discontinuation process. Those still taking their injectable medication at the time of wave 1 were contacted 6 months later (wave 2, n = 585) to assess any changes in their medication experience. FINDINGS: Among patients who delayed filling their prescription by ≥1 week, cost was a common reason for delay for refilling of liraglutide (63%) and exenatide QW (49%). The most commonly reported barrier to maintaining injectable medication was injection concerns (42%) such as aversion to needles, pain, or needle size. Lack of perceived need was the most common reason for discontinuation for basal (47%) and prandial/premixed (44%) insulin. For liraglutide, the most common reason for discontinuation was experiencing an adverse event (33%); for exenatide QW, it was injection concerns (38%). IMPLICATIONS: The diverse barriers we identified underscore the need for better patient-prescriber communication to ensure that newly prescribed injectable medications are consistent with a patient's ability or willingness to manage them, to appropriately set expectations about medications, and to address new barriers that arise during the course of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Adherence to Long‐Term Therapies: Evidence for Action
Burkhart, P. V., & Sabaté, E. (2003) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2003.tb00001.x · Cited by 2,526
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407 · cited 2×
“These concerns are consistent with previous data showing that 33% of patients are anxious about taking their insulin injections.(29,30) For those who were prescribed exenatide QW, the relatively high frequency of injection concerns may be related to patient concern over the 8-mm, 23-gauge needle, the required mixing p…”
ResultPiette, J. D., Heisler, M., & Wagner, T. H. (2004) · American Journal of Public Health · doi:10.2105/ajph.94.10.1782 · Cited by 349 · cited 1×
“The economic burden of injectable drugs, particularly GLP-1RAs, may influence decisions on medication choice and persistence.(38,39) In a study of patients with type 2 diabetes from an economically burdened region in which up to 50% underused their medication, cost was cited as a primary reason for underuse.”
BackgroundAdherence to healthy lifestyle habits in US adults, 1988–2006
King, D. E., Mainous, A. G., Carnemolla, M., & Everett, C. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.11.013 · Cited by 336 · cited 1×
“INTRODUCTION Patients with type 2 diabetes typically fail to address hyperglycemia with diet and exercise and require pharmacotherapy for disease control.(1,2) Adherence, defined by the World Health Organization as “the extent to which a person’s behavior-taking medication, following a diet, and/or executing lifestyle…”
BackgroundJha, A. K., Aubert, R. E., Yao, J., Teagarden, J. R., & Epstein, R. S. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1198 · Cited by 174
Lopez, J., Annunziata, K., Bailey, R., Morisky, D. E., & Rupnow, M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58813 · Cited by 96
Cited by
Advances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Materials for oral delivery of proteins and peptides
Brown, T. D., Whitehead, K. A., & Mitragotri, S. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0156-6 · Cited by 520
Efficacy of semaglutide in a subcutaneous and an oral formulation
Meier, J. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645617 · Cited by 146
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
Aroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135
Metadata
- Authors
- Spain, C. V., Wright, J. J., Hahn, R. M., Wivel, A., & Martin, A. A.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 38
- Issue
- 7
- Pages
- 1653-1664.e1
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2463562243
- Cited by
- 117
- References
- 12
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes. https://app.cochat.ai/papers/10.1016/j.clinthera.2016.05.009
- The paper
- Spain, C. V., Wright, J. J., Hahn, R. M., Wivel, A., & Martin, A. A. (2016). Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes. Clinical Therapeutics. https://doi.org/10.1016/j.clinthera.2016.05.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.